Clinical Trial Update: A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites. [Phase 1]

View source ↗

Summary

This Phase 1 trial demonstrates the bioequivalence of Rosiglitazone XR 8 mg extended-release capsules manufactured at two different sites, and the study has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rosiglitazone XR (rosiglitazone extended-release)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED